Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

@article{Caon2006ClinicalCA,
  title={Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.},
  author={Christina Caon and M. Azfar Din and Willie L Ching and Alexandros C. Tselis and Robert P. Lisak and Omar A. Khan},
  journal={European journal of neurology},
  year={2006},
  volume={13 5},
  pages={471-4}
}
We examined the clinical course after switching disease-modifying therapy (DMT) in patients with relapsing-remitting multiple sclerosis (RRMS). Eighty-five consecutive RRMS patients who received weekly interferon beta-1a (IFN beta-1a) 6 MU i.m. for at least 18 months were enrolled. Baseline annualized relapse rate (ARR) for the 2 years prior to initiating therapy with IFN beta-1a was obtained from charts. All 85 patients received treatment with IFN beta-1a at 6 MU i.m. weekly for 18-24 months… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…